TABLE 1

Oncology-related drugs that induce in vitro antifungal resistance in Candida and Aspergillus cellsa

OrganismAntifungal (concentration)CompoundRelative growth (×)Z-score
C. albicansNoneNone2.8535.62
Fluconazole (1 μM)None1.00
Tamoxifen2.5431.29
Epirubicin2.5832.17
Idarubicin3.9259.4
Nilotinib2.8337.3
Ceritinib3.244.72
Daunorubicin2.4529.52
Cabazitaxel3.1142.96
Doxorubicin2.0120.51
C. glabrataNoneNone4.8562.52
Fluconazole (100 μM)None1.00
Megestrol2.1518.61
Fluorouracil3.8746.59
Exemestane4.4155.25
Lomustine3.2937.2
Ixazomib216.27
Regorafenib3.4539.73
Abiraterone4.6459.04
Daunorubicin3.2336.12
Dactinomycin4.5557.6
Romidepsin2.3822.4
Omacetaxine mepesuccinate4.3253.81
C. glabrataNoneNone9.9389.36
Caspofungin (500 nM)None1.00
Tretinoin5.0440.37
A. fumigatusNoneNone
Voriconazole (2 μg/ml)None
Fluorouracil
Thioguanine
Floxuridine
  • a A small collection of FDA-approved oncolytic agents was tested for each compound's ability to antagonize antifungal activity against several common human fungal pathogens in 96-well format at a final test compound concentration of 5 μM. For C. albicans and C. glabrata wells, hits were defined as compounds that resulted in an OD600 of at least twice that of control wells treated with antifungal alone and are listed here with their relative growth and Z-scores. For A. fumigatus, hits were called based on visual inspection of the wells, due to the unreliable nature of OD reads with filamentous fungi.